Olomorasib Plus chemoimmunotherapy Demonstrates Durable Efficacy as First-Line Treatment in KRAS G12C-Mutant Non-Small Cell Lung Cancer
Clinical Summary
- Updated results from the LOXO-RAS-20001 and SUNRAY-01 trials demonstrated promising antitumor activity with first-line olomorasib plus pembrolizumab, pemetrexed, and carboplatin in patients with advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC), with a confirmed objective response rate of 62% and disease control rate of 90%.
- With an additional 9 months of follow-up, the combination achieved a median duration of response of 14 months and median progression-free survival of 11.6 months, with no new safety signals or treatment discontinuations due to treatment-related adverse events.
- Hepatic adverse events were manageable with dose modifications and/or corticosteroids, and the randomized phase of SUNRAY-01 will further evaluate the efficacy and safety of adding olomorasib to first-line chemoimmunotherapy, with results anticipated in 2027.
Marcelo V. Negrao, MD, associate professor at The University of Texas MD Anderson Cancer Center in Houston, discusses updated findings from the LOXO-RAS-20001 and SUNRAY-01 trials, presented at the 2026 European Society for Medical Oncology (ESMO) Congress. The integrated analysis evaluated olomorasib, a KRAS G12C inhibitor, in combination with pembrolizumab, pemetrexed, and carboplatin as first-line treatment for patients with advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC). With an additional 9 months of follow-up, the combination demonstrated a confirmed objective response rate of 62%, a disease control rate of 90%, a median duration of response of 14 months, and median progression-free survival of 11.6 months.
Negrao reports that the combination maintained a manageable safety profile, with no new safety signals or treatment discontinuations attributed to treatment-related adverse events. Hepatic adverse events occurred at a median of 43 days, had a median duration of 4 days, and resolved with dose reductions and/or corticosteroids when needed. No confirmed cases meeting Hy's law criteria were reported, and prophylactic measures for olomorasib-related toxicities were not required. These findings support continued investigation of olomorasib-based chemoimmunotherapy as a potential first-line treatment strategy for KRAS G12C-mutant NSCLC. The randomized phase of SUNRAY-01, which compares olomorasib plus chemoimmunotherapy with placebo plus chemoimmunotherapy regardless of PD-L1 expression, has completed enrollment, with results expected in 2027.
Transcript
Marcelo V. Negrao, MD: My name is Marcelo Negrao. I'm an associate professor at MD Anderson Cancer Center in Houston, Texas, and I'm here to present the updated results of the integrated analysis of LOXO-RAS-20001 and the safety lead-in cohort of the SUNRAY-01 trials for patients with first-line advanced KRAS G12C-mutant NSCLC.
This data disclosure presents an updated analysis with an additional 9 months of follow-up time of patients who were treated with olomorasib plus pembrolizumab, pemetrexed, and carboplatin chemotherapy at standard doses for first-line treatment in this disease setting.
What we show is that this combination produced a confirmed objective response rate of 62%, a disease control rate of 90%. The median duration of response was 14 months, and the median progression-free survival was 11.6 months.
With additional follow-up time, we observed no new safety signals compared to prior disclosures. No patients discontinued treatment due to treatment-related adverse events, and the combination continues to show a manageable and favorable safety profile.
Hepatic events occurred at a median of 43 days, and the median duration was 4 days. All of these events resolved with dose reductions and/or corticosteroids when needed, and no patients discontinued the treatment regimen due to hepatic events. There were no confirmed cases meeting Hy's law criteria.
To summarize our findings, this combination of olomorasib and chemoimmunotherapy in the first-line setting continues to show promising and durable efficacy in patients who are treatment-naive with advanced KRAS G12C-mutant NSCLC. The toxicity profile continues to remain manageable and controlled with dose reductions, dose adjustments, and/or corticosteroids as needed. In addition to that, we also highlight that there was no requirement for prophylactic measures for olomorasib-related toxicities in both of these studies.
Furthermore, Part B of the SUNRAY-01 trial, which is the randomized cohort of chemoimmunotherapy plus olomorasib or placebo for first-line treatment of advanced KRAS G12C-mutant NSCLC, irrespective of PD-L1 expression, has completed enrollment, with data disclosure planned for 2027.
Thank you for your time and attention.
Source
Negrao MV, Uyeki J, Cicin I, et al. First-line (1L) olomorasib + chemoimmunotherapy (chemo-IO) in KRAS G12C-mutant NSCLC: updated results from the LOXO-RAS-20001 and SUNRAY-01 trials. Presented at: ESMO Congress 2026; October 23-27, 2026; Madrid, Spain. Abstract 2652RO.
© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of LL&M, Oncology Learning Network or HMP Global, their employees, and affiliates.


